spacer
home > epc > spring 2009 > oncology: biomarkers promise progress
PUBLICATIONS
European Pharmaceutical Contractor

Oncology: Biomarkers Promise Progress

The discovery and development of novel drugs remains a process fraught with high attrition rates and many technological, scientific and financial challenges. The cost to bring a new drug to market is estimated at $800 million and is predicted to increase 7.4 per cent above inflation on an annual basis (1). Over 75 per cent of these costs are expended on unsuccessful compounds and, in spite of billions spent on preclinical and clinical studies, post-launch withdrawal of compounds due to adverse side effects still occurs. Opportunities for the pharmaceutical industry lie in the integration of discovery and development functions to bring affordable, effective and safe drugs to patients. Many drug candidates still fail in clinical studies because we cannot accurately predict how effective or how safe these candidates will be in humans based solely on animal studies. Knowing the pharmacokinetics and pharmacodynamics of a drug candidate and the response of a patient to therapeutic intervention is crucial to successfully designing effective clinical trials. Biomarker technologies that are able to increase understanding of a drug’s mechanism of action at an early stage, precise dosing, and a regime of administration will generate valuable information on the drugs activity and accelerate the drug development process (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Lydia Meyer-Turkson is Director of the Biomarker Division at Epistem Ltd. She has a BSc honours and MPhil postgraduate degree in Chemistry from University College Cardiff and received an MBA from Manchester Business School. She has over 15 years business development experience in the contract research sector, setting up drug discovery and development collaborations between biotech and pharmaceutical companies across Europe and the US. She recently joined Epistem from a role as VP Business Development at Evotec AG.

spacer
Lydia Meyer-Turkson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement